Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Trevena, Inc.
  6. News
  7. Summary
    TRVN   US89532E1091

TREVENA, INC.

(TRVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TREVENA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

06/16/2021 | 04:11pm EDT

Item 7.01 Regulation FD Disclosure

On June 16, 2021, Trevena, Inc. (the "Company") updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit 99.1.

The information set forth on this Item 7.01 and furnished hereto as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
No.                                      Description
  99.1       Corporate Presentation Deck dated June 16, 2021
104        The cover page from this Current Report on Form 8-K, formatted in
           Inline XBRL

© Edgar Online, source Glimpses

All news about TREVENA, INC.
07/26TREVENA : Begins NIH-Funded Trial of COVID-19 Therapeutic
MT
07/26TREVENA : Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Tri..
AQ
07/26Trevena, Inc. Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tis..
CI
07/23Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shar..
GL
07/12TREVENA : Announces Publication of OLINVYK« Health Economic Model in Journal of ..
AQ
07/12Trevena Announces Publication of OLINVYK« Health Economic Model in Journal of..
CI
07/08TREVENA : Enrolls First Patient in Late-Stage Study of Olinvyk Injection in Chin..
MT
07/08Trevena Announces First Patient Enrolled in OLINVYK« Phase 3 Trial in China i..
GL
07/07TREVENA : Launches Study to Assess Physiologic Impact of Olinvyk on Respiratory ..
MT
07/07Trevena Announces Initiation of OLINVYK« Respiratory Physiology Study Includi..
GL
More news
Financials (USD)
Sales 2021 8,82 M - -
Net income 2021 -45,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,63x
Yield 2021 -
Capitalization 219 M 219 M -
Capi. / Sales 2021 24,8x
Capi. / Sales 2022 8,34x
Nbr of Employees -
Free-Float 98,9%
Chart TREVENA, INC.
Duration : Period :
Trevena, Inc. Technical Analysis Chart | TRVN | US89532E1091 | MarketScreener
Technical analysis trends TREVENA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,33 $
Average target price 5,33 $
Spread / Average Target 301%
EPS Revisions
Managers and Directors
Carrie L. Bourdow President, Chief Executive Officer & Director
Barry Shin Chief Financial Officer & Senior Vice President
Leon O. Moulder Chairman
Mark A. Demitrack Chief Medical Officer & Senior Vice President
Michael J. Fossler VP-Clinical Development & Quantitative Sciences
Sector and Competitors
1st jan.Capi. (M$)
TREVENA, INC.-37.85%219
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-14.71%52 296